605 METFORMIN TREATMENT REDUCES HEPATOCELLULAR CARCINOMA (HCC) RISK IN PATIENTS WITH CIRRHOSIS C: A RETROSPECTIVE OBSERVATIONAL STUDY OF TWO INDEPENDENT COHORTS

2012 ◽  
Vol 56 ◽  
pp. S240
Author(s):  
J. Ampuero ◽  
M. Fernández-Gil ◽  
D. Núñez ◽  
S. Alonso ◽  
M. Maraver ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Observational Study ◽  
Retrospective Observational Study ◽  
Metformin Treatment

scholarly journals Comparison of Ablation Area and Change in Functional Liver Reserve after Radiofrequency Ablation for Hepatocellular Carcinoma Using the arfa® and VIVA® Systems

2022 ◽  
Vol 11 (2) ◽  
pp. 434
Author(s):  
Hiroaki Takaya ◽  
Tadashi Namisaki ◽  
Kazusuke Matsumoto ◽  
Junya Suzuki ◽  
Koji Murata ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Observational Study ◽  
Total Bilirubin ◽  
Retrospective Observational Study ◽  
Ablation Area ◽  
Hepatocellular Carcinomas ◽  
The Difference ◽  
Clinical Problems

Radiofrequency ablation (RFA) is recommended in Japan for patients with hepatocellular carcinomas (HCCs) one to three in number and ≤3 cm in size. The arfa® and VIVA® RFA systems are widely used for patients with HCC and this retrospective observational study aims to compare their performances. The study included 365 patients with HCCs one to three in number and ≤3 cm in size who underwent RFA using the arfa® system (arfa® group) or the VIVA® system (VIVA® group). The total bilirubin (T-Bil) level after RFA was higher in the arfa® group than in the VIVA® group. With a 3-cm electrode needle, the longest diameter (Dmax) and the shortest diameter were analyzed and found to be greater in the arfa® group than in the VIVA® group. Furthermore, Dmax with the 2.5-cm electrode needle was greater in the arfa® group than in the VIVA® group. Statistically significant differences in the ablation area and in the T-Bil value after RFA were observed between the groups; however, these differences are not considered clinical problems because the difference in the ablation area was only slight and the Child–Pugh score was the same between the groups. Thus, hepatologists can use either of the RFA systems based on their preference.

Hemmkörperentwicklung bei Hämophilie-Patienten nach Präparate wechsel

2012 ◽  
Vol 32 (S 01) ◽  
pp. S39-S42 ◽  
Author(s):  
S. Kocher ◽  
G. Asmelash ◽  
V. Makki ◽  
S. Müller ◽  
S. Krekeler ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Observational Study ◽  
Retrospective Observational Study ◽  
Frequent Change ◽  
Patient Age ◽  
Treatment Regimens ◽  
Patient Âgé ◽  
The Relationship ◽  
Observation Period

SummaryThe retrospective observational study surveys the relationship between development of inhibitors in the treatment of haemophilia patients and risk factors such as changing FVIII products. A total of 119 patients were included in this study, 198 changes of FVIII products were evaluated. Results: During the observation period of 12 months none of the patients developed an inhibitor, which was temporally associated with a change of FVIII products. A frequent change of FVIII products didn’t lead to an increase in inhibitor risk. The change between plasmatic and recombinant preparations could not be confirmed as a risk factor. Furthermore, no correlation between treatment regimens, severity, patient age and comorbidities of the patients could be found.

Sign in / Sign up

Export Citation Format

Share Document